Matthew Keller
Stock Analyst at HC Wainwright & Co.
(0.29)
# 4,184
Out of 5,131 analysts
10
Total ratings
18.18%
Success rate
-22.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IFRX InflaRx | Reiterates: Buy | $6 | $1.04 | +476.92% | 2 | Dec 30, 2025 | |
| GALT Galectin Therapeutics | Maintains: Buy | $6 → $11 | $3.15 | +249.21% | 2 | Dec 17, 2025 | |
| SXTP 60 Degrees Pharmaceuticals | Assumes: Buy | $6 | $0.53 | +1,039.82% | 1 | Nov 14, 2025 | |
| SNSE Sensei Biotherapeutics | Downgrades: Neutral | n/a | $11.62 | - | 1 | Oct 30, 2025 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $31 | $2.93 | +958.02% | 2 | Sep 30, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $7.40 | +143.24% | 1 | Aug 26, 2025 | |
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $1.16 | +1,106.90% | 1 | Aug 15, 2025 |
InflaRx
Dec 30, 2025
Reiterates: Buy
Price Target: $6
Current: $1.04
Upside: +476.92%
Galectin Therapeutics
Dec 17, 2025
Maintains: Buy
Price Target: $6 → $11
Current: $3.15
Upside: +249.21%
60 Degrees Pharmaceuticals
Nov 14, 2025
Assumes: Buy
Price Target: $6
Current: $0.53
Upside: +1,039.82%
Sensei Biotherapeutics
Oct 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $11.62
Upside: -
Acurx Pharmaceuticals
Sep 30, 2025
Reiterates: Buy
Price Target: $31
Current: $2.93
Upside: +958.02%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $7.40
Upside: +143.24%
Phio Pharmaceuticals
Aug 15, 2025
Reiterates: Buy
Price Target: $14
Current: $1.16
Upside: +1,106.90%